견적문의

IRVING, TEXAS--( / )--Lightbeam Health Solutions, the leader in end-to-end population health management solutions and services, is proud to announce their partnership with Ambry Genetics, a Konica Minolta Precision Medicine (KMPM) company. The partnership provides precision genetic testing data within the Lightbeam application to help organizations predict increased risk for common cancers and chronic conditions within patient populations.

According to the Centers for Disease Control and Prevention, 1.6 million people are diagnosed with cancer each year in the United States. The Ambry Genetics-Lightbeam partnership is expected to reduce this burden with tools for early detection and prevention by allowing providers to quickly identify, assess, and engage patients who meet specific risk factors. As the body of genetic evidence expands, so too will the value brought to mutual clients of Lightbeam and Ambry Genetics.

The CARE (Comprehensive, Assessment, Risk and Education) Program™ will integrate into the Lightbeam Platform, providing an additional clinical data stream for clients to enhance Lightbeam’s proprietary Ability-to-Impact (ATI) risk score. Genetic risk information is critical because it informs personalized patient care to include preventive surgeries, increased cancer screening, and in some cases, targeted therapies.

“At Lightbeam, part of our vision is to help organizations transform care delivery from being reactive to proactive,” said Pat Cline, CEO of Lightbeam. “We believe this partnership with Ambry Genetics will positively impact lives with its ability to indicate whether a person is high-risk for cancer or other diseases. In combination with our industry-leading analytics platform, Ambry’s genetic data further enhances how Lightbeam clients can improve quality, reduce costs, and positively impact outcomes for the populations they serve.”

“Today, only a fraction of individuals with a hereditary predisposition to disease are tested,” said Rob Guigley, Chief Commercial Officer, Ambry Genetics. “Our partnership with Lightbeam intends to bring greater access to the community and empower patients and providers to make informed preventative decisions that can improve health care and management. The potential impact of this relationship is significant for patients, providers, and payors.”

For more information on this innovative partnership, visit the Lightbeam Health booth, #2060 in the Sands Expo, at HIMSS21 in Las Vegas, Nevada, from August 9-13, 2021.

About AMBRY GENETICS ®

Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions.

About Lightbeam Health Solutions

Lightbeam Health Solutions delivers a revolutionary model for managing patient populations and associated risk. Lightbeam’s vision is to bring health data into the light through the use of analytics, and to provide the insight and capabilities healthcare clients need to ensure patients receive the right care at the right time. Lightbeam’s platform facilitates end-to-end population health management for ACOs, payers, provider groups, health systems, and other healthcare organizations aspiring to provide superior care at a lower cost. For more information, visit , and follow Lightbeam on LinkedIn and Twitter.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

PARIS & DUBLIN--( / )--OSKARE CAPITAL SAS today launches OSKARE Fund I together with cannabinoid industry veteran Bruce Linton. The EU based wankoz 미나걸 fund targets next generation cannabinoid therapies and related industry infrastructure, leveraging the expertise and track record of the founding team in medicine, wankoz engineering, chemistry, venture capital, and intellectual property.

“Based on my partnership with the OSKARE CAPITAL team over the last 9 months, I am convinced that Europe has wankoz 툰코 the optimal regulatory and research environment to build the future key players in the global medical cannabinoid industry,” said Bruce Linton, Co-founder and non- Executive Chairman, OSKARE CAPITAL, and former CEO and Founder, Canopy Growth. wankoz 일일툰 “The OSKARE CAPITAL team’s strong scientific background and proven track record in pharma, venture capital and IP protection leverages proprietary deal flow and knowledge of the ecosystem to be successful”.

The fund will invest in a diversified portfolio wankoz 오레오툰 of companies with disruptive technology and strong barriers to entry. The team is supported wankoz 조건女공유/후기/분양 by a highly experienced senior advisory board () that provides critical expertise and expands COMIC Thenetwork. OSKARE Fund I is ESG compatible.

Medical grade cannabinoid-based products are already approved and used in Europe to treat conditions such as epilepsy, multiple sclerosis and chronic pain. Now the science and wankoz 미국구입 the medical community are driving opportunities in human as well as animal health and wellness.

The team at OSKARE CAPITAL has wankoz 애니119 access to leading wankoz 냥코스페이스 research teams and companies that have identified new cannabinoid molecules and formulations with therapeutic potential for medical conditions such as anxiety and depression, cancer, autism, ADHD, cardiovascular and inflammatory skin conditions, among others. The fund will invest in the entire value chain as well as look to valorise hemp and cannabis biomass for new sustainable material applications.

The team has wankoz already performed a first investment wankoz 팩트스포 전화방/퇴폐이용원/안마등 TheDenmark’s Octarine Bio. wankoz

Innovation wankoz and R&D are at the core of EU and UK value generation and core to the 화동맞고 스포츠중계털보TV Fund opportunity. Cannabinoids will wankoz 스포츠중계블랙TV disrupt global markets from food to pharma and OSKARE CAPITAL will be the early investor on 야마구치리코 Innovationwave.

About 스즈무라아이리 Aboutwankoz CAPITAL SAS - wankoz 토토랑프로토랑 oskarecapital.com

OSKARE CAPITAL SAS is a French company which has the French 봉가캠 OSKAREof wankoz 정우성카페 CIF (Financial Investment Advisor), ORIAS number 20001206 and regulated by the wankoz AMF.

About OSKARE FUND wankoz 실비에정 I

OSKARE Fund I, advised by OSKARE CAPITAL SAS, is set up so that investors can readily access innovative opportunities in this space with the protection and transparency an AIFM compatible fund wankoz 러피안정 provides. Regulated by the 할배 OSKAREBank of Ireland, Crossroads Capital Management wankoz 오예스알바 Limited will act as an alternative investment fund manager.

About Crossroads Capital Management wankoz 브라질투데이 Limited - wankoz 프레야지정

Crossroads Capital Management Limited, majority 화동맞고 아드레닌 owned by Hauck & Aufhauser Fund Services S.A., is authorised and regulated by the Central Bank of Ireland wankoz 레이디알바 as a UCITS management company and alternative investment wankoz fund manager (AIFM).

This press release is not a marketing communication in the European Union wankoz 성인영화 member states or non-member 상장동성인게임장 Thiswankoz 주블리아 This press release is not an offer of securities, products, instruments or services for sale in the United wankoz 섹스 States. We do not make representation that information presented is appropriate for use in all jurisdictions.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the wankoz 아시아야동 industry’s largest press release distribution network